Recent developments on foaming mechanical and electronic techniques for the management of varicose veins

Expert Review of Medical Devices

Volumn 16, Issue 11, 2019, Pages 931-940

  Critello, C Davide ^a   Pullano, Salvatore A ^a   Matula, Thomas J ^b   De Franciscis, Stefano ^a   Serra, Raffaele ^a   Fiorillo, Antonino S ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Device; foam; foaming techniques; sclerotherapy; varicose veins

Indexed keywords

CARDIOVASCULAR SYSTEM; COST EFFECTIVENESS; FOAMS;

BLOOD CIRCULATION; BUBBLE SIZE DISTRIBUTIONS; DEVICE; ELECTRONIC TECHNIQUE; MINIMALLY INVASIVE; SCLEROTHERAPY; THERAPEUTIC PROCEDURES; VARICOSE VEINS;

BUBBLES (IN FLUIDS);

POLIDOCANOL;

COST EFFECTIVENESS ANALYSIS; FOAM; FOAM SCLEROTHERAPY; FOAM STABILITY; HUMAN; MICROBUBBLE; PATIENT SAFETY; REVIEW; SCLEROTHERAPY; THERAPY EFFECT; VARICOSIS; MEDICAL ELECTRONICS; PROCEDURES; TREATMENT OUTCOME; ULTRASOUND;

ELECTRONICS, MEDICAL; HUMANS; SCLEROTHERAPY; TREATMENT OUTCOME; ULTRASONICS; VARICOSE VEINS;

EID: 85074476679     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1080/17434440.2019.1682549     Document Type: Review

References (101)

1. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the society for vascular surgery and the american venous forum. J Vasc Surg. 2011;53(5):2S–48S.
2. van der Velden SK, Pichot O, van de Bos RR, et al. Management strategies for patients with varicose veins (C2eC6): results of a worldwide survey. Eur J Vasc Endovasc Surg. 2015;49:213–220.
3. Riding DM, Hansrani V, McCollum C., Pelvic vein incompetence: clinical perspectives. Vasc Health Risk Manag. 2017;13:439–447.
4. Beale RJ, Gough MJ., Treatment options for primary varicose veins—a review. Eur J Vasc Endovasc Surg. 2005;30:83–95.
5. Niedzwiecki G. Endovenous thermal ablation of the saphenous vein. Seminar Intervent Radiol. 2005;22(3):204–208.
6. Subramonia S, Lees T. Sensory abnormalities and bruising after long saphenous vein stripping: impact on short–term quality of life. J Vasc Surg. 2005;42(3):510–514.
7. Spinedi L, Uthoff H, Partovi S, et al. Varicosities of the lower extremity, new approaches: cosmetic or therapeutic needs? Swiss Med Wkly. 2016;146:w14360.
8. Brittenden J, Cotton SC, Elders A, et al. Clinical effectiveness and cost–effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technol Assess. 2015;19(27):1–342.
9. Hirsch T. Varicose vein therapy and nerve lesions. Vasa. 2017;46(2):96–100.
10. Myers K. A history of injection treatments–II sclerotherapy [published online ahead of print October 18, 2018]. Phlebology. doi:10.1177/0268355518798283
11. Frullini A. Foam sclerotherapy: A review. Phlebolymphology. 2003;40(40):125–129.
12. Colletti G, Deganello A, Bardazzi A, et al. Complications after treatment of head and neck venous malformations with sodium tetradecyl sulfate foam. J Craniofac Surg. 2017;28(4):e388–e392.
13. Hill DA. Neurological and chest symptoms following sclerotherapy: A single centre experience. Phlebology. 2013;29(9):619–627.
14. Rabe E, Breu FX, Cavezzi A, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29(6):338–354.
15. Urso ML, Ward KG. Transient ischemic attack after foam sclerotherapy. J Am Osteopath Assoc. 2016;116(9):571–572.
16. Kim M, Niroumandpour M, Poustinchian B. Transient ischemic attack after foam sclerotherapy in a woman with a patent foramen ovale. J Am Osteopath Assoc. 2016;116(5):320–323.
17. Malvehy MA, Asbjornsen C. Transient neurologic event following administration of foam sclerotherapy. Phlebology. 2016;32(1):66–68.
18. Guex J–J. Complications and side–effects of foam sclerotherapy. Phlebology. 2009;24(6):270–274.
19. Asbjornsen CB, Rogers CD, Russell BL. Middle cerebral air embolism after foam sclerotherapy. Phlebology. 2012;27(8):430–433.
20. Wright DD, Gibson KD, Barclay J, et al. High prevalence of right–to–left shunt in patients with symptomatic great saphenous incompetence and varicose veins. J Vasc Surg. 2010;51:104–107.
21. Frullini A, Barsotti MC, Santoni T, et al. Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg. 2012;38(5):741–747.
22. Wong M. Should foam made with physiologic gases be the standard in sclerotherapy? Phlebology. 2014;30(9):580–586.
23. Connor DE, Cooley–Andrade O, Goh WX, et al. Detergent sclerosants are deactivated and consumed by circulating blood cells. Eur J Vasc Endovasc Surg. 2015;49(4):426–431.
24. Sounderajah V, Moore H, Thapar A, et al. Acoustic reflectors are visible in the right heart during radiofrequency ablation of varicose veins. Phlebology. 2015;30(8):557–563.
25. Moon K, Dharmarajah B, Bootun R, et al. Comparison of microbubble presence in the right heart during mechanochemical and radiofrequency ablation for varicose veins. Phlebology. 2017;32(6):425–432.
26. Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol. 2013;112:1039–1045.
27. Kume G, Gallotti M, Nunes G. Review on anionic/cationic surfactant mixtures. J Surfactants Deterg. 2008;11:1–11.
28. Duffy DM. Sclerosants: a comparative review. Dermatol Surg. 2010;36(suppl2):1010–1025.
29. Hwang JH, Zhou Y, Warren C, et al. Targeted venous occlusion using pulsed high–intensity focused ultrasound. IEEE Trans Biomed Eng. 2010;57(1):37–40.
30. Whiteley MS, Dos Santos SJ, Fernandez–Hart TJ, et al. Media damage following detergent sclerotherapy appears to be secondary to the induction of inflammation and apoptosis: an immunohistochemical study elucidating previous histological observations. Eur J Vasc Endovasc Surg. 2016;51(3):421–428.
31. Coker Kayode A. Physical properties of liquids and gases (Appendix C). In: Coker KA, editor. Ludwig’s applied process design for chemical and petrochemical plants. 4th ed. Vol. 1, Oxford (UK): Elsevier Inc; 2007. p. 855.
32. Chen A–W, Liu S–H, Huang Y–Y, et al. Preliminary experience with more stable polidocanol foam in sclerotherapy of head and neck venous malformations. Dermatol Surg. 2018;44(11):1421–1426.
33. Murray BS. Stabilization of bubbles and foams. Curr Opin Colloid Interface Sci. 2007;12(4–5):232–241.
34. Sun Q, Tan L, Wang G. Liquid foam drainage: an overview. Int J Mod Phys B. 2008;22(15):2333–2354.
35. Carugo D, Ankrett DN, O’Byrne V, et al. The role of clinically–relevant parameters on the cohesiveness of sclerosing foam in a biomimetic vein model. J Mater Sci Mater Med. 2015;26(11):258.
36. Peterson JD, Goldman MP. An investigation into the influence of various gases and concentrations of sclerosants on foam stability. Dermatol Surg. 2011;37(1):12–17.
37. Cameron E, Chen T, Connor DE, et al. Sclerosant foam structure and stability is strongly influenced by liquid air fraction. Eur J Vasc Endovasc Surg. 2013;46:488–494.
38. Nastasa V, Samaras K, Ampatzidis C, et al. Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm. 2015;478(2):588–596.
39. Critello CD, Fiorillo AS, Cristiano MC, et al. Effects of sulodexide on stability of sclerosing foams. Phlebology. 2019;3(1):191–200.
40. Bai T, Liu Y, Liu J, et al. A comparison of different surfactants on foam stability in foam sclerotherapy in vitro. J Vasc Surg. 2019;69(2):581–591.e1.
41. Chen A–W, Liu YR, Li K, et al. An investigation on the influence of hyaluronic acid on polidocanol foam stability. Dermatol Surg. 2016;42(1):56–58.
42. Magrabi SA, Dlugogorski BZ, Jameson GJ. Bubble size distribution and coarsening of aqueous foam. Chem Eng Sci. 1999;54:4007–4022.
43. Critello CD, Fiorillo AS, Matula TJ. Size of sclerosing foams prepared by ultrasound, mechanical agitation, and the handmade Tessari method for treatment of varicose veins. J Ultrasound Med. 2017;36(3):649–658.
44. Valenzuela GC, Wong K, Connor DE, et al. Foam sclerosants are more stable at lower temperatures. Eur J Vasc Endovasc Surg. 2013;46(5):593–599.
45. Bai T, Jiang W, Chen Y, et al. Effect of multiple factors on foam stability in foam sclerotherapy. Sci Rep. 2018;8:1.
46. Drenckhan W, Saint–Jalmes A. The science of foaming. Adv Colloid Interface Sci. 2015;222:228–259.
47. Unger E, Porter T, Lindner J, et al. Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Deliv Rev. 2014;7:110126.
48. Crake C, Papademetriou IT, Zhang Y, et al. Simultaneous passive acoustic mapping and magnetic resonance thermometry for monitoring of cavitation–enhanced tumor ablation in rabbits using focused ultrasound and phase–shift nanoemulsions. Ultrasound Med Biol. 2018;44(12):2609–2624.
49. Bailey MR, Pishchalnikov YA, Sapozhnikov OA, et al. Cavitation detection during shock–wave lithotripsy. Ultrasound Med Biol. 2005;31(9):1245–1256.
50. Khokhlova VA, Fowlkes JB, Roberts WW, et al. Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia. 2015;31(2):145–162.
51. Leong T, Ashokkumar M, Kentish S. The fundamentals of power ultrasound–A review. Acoust Aust. 2011;39(2):54–63.
52. Wollmann JC. The history of sclerosing foams. Dermatol Surg. 2004;30(5):694–703.
53. Tessari L. Nouvelle technique d’obtention de la sclera–mousse. Phlebologie. 2000;53:129–133.
54. Carugo D, Ankrett DN, Zhao X, et al. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician–compounded foams. Phlebology. 2016;31:283–295.
55. Rao J, Goldman MP. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double–syringe system technique. Dermatol Surg. 2005;31(1):19–22.
56. VAN Deurzen B, Ceulen RP, Tellings SS, et al. Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg. 2011;37(10):1448–1455.
57. McAree B, Ikponmwosa A, Brockbank K, et al. Comparative Stability of Sodium Tetradecyl Sulphate (STD) and polidoncal foam: impact on vein damage in an In–vitro model. Eur J Vasc Endovasc Surg. 2012;43(6):721–725.
58. Rial R, Hervas LS, Monux G, et al. Polidocanol foam stability in terms of its association with glycerin. Phlebology. 2015;29(5):304–309.
59. Cilurzo F, Critello CD, Paolino D, et al. Polydocanol foam stabilized by liposomes: supramolecular nanoconstructs for sclerotherapy. Colloids Surf B Biointerfaces. 2019;1(175):469–476.
60. Lai SW, Goldman MP. Does the relative silicone content of different syringes affect the stability of foam in sclerotherapy? J Drugs Dermatol. 2008;7(4):399–400.
61. Patel SB, Ostler AE, Dos Santos SJ, et al. The effects of environmental and compositional manipulations on the longevity of Tessari–made foam for sclerotherapy. J Vasc Surg Venous Lymphat Disord. 2015;3(3):312–318.
62. Whiteley MS, Patel SB. Modified Tessari Tourbillon technique for making foam sclerotherapy with silicon–free syringes. Phlebology. 2015;30(9):614–617.
63. McMaster S. Sodium tetradecyl sulphate foam stability prior to injection: factors affecting liquid reformation. Phlebology. 2011;26(6):222–226.
64. Bai T, Jiang W, Fan Y. Influence of syringe volume on foam stability in sclerotherapy for varicose vein treatment. Dermatol Surg. 2018;44(5):689–696.
65. Shirazi AR, Goldman M. The use of a 5–micron filter hub increases foam stability when using the double–syringe technique. Dermatol Surg. 2008;34(1):91–92.
66. Wollmann JC. Sclerosant foams: stabilities, physical properties and rheological behavior. Phlebologie Stuttgart. 2010;39(4):208–217.
67. Morrison N, Neuhardt DL, Rogers CR, et al. Incidence of side effects using carbon dioxide–oxygen foam for chemical ablation of superficial veins of the lower extremity. Eur J Vasc Endovasc Surg. 2010;40(3):407–413.
68. Hesse G, Breu FX, Kuschmann A, et al. Sclerotherapy using air– or CO2–O2–foam. Phlebologie. 2012;41(2):77–88.
69. Hamel–Desnos C, Ouvry P, Benigni J–P, et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double–blind trial with 2 year–follow–up. “The 3/1 Study”. Eur J Vasc Endovasc Surg. 2007;34(6):723–729.
70. Bai T, Chen Y, Jiang W, et al. Studies on foam decay trend and influence of temperature jump on foam stability in sclerotherapy. Vasc Endovascular Surg. 2018;52(2):98–106.
71. Todd III KL, Wright DI, Orfe E. The durability of polidocanol endovenous microfoam treatment effect on varicose vein symptoms and appearance in patients with saphenofemoral junction incompetence: one–year results from the VANISH–2 study. J Vasc Surg Venous Lymphat Disord. 2015;2(1):258–264.
72. Redondo P, Cabrera J. Microfoam sclerotherapy. Semin Cutan Med Surg. 2005;24(4):175–183.
73. Cabrera J, Jr, García–Olmedo MA. Treatment of varicose long saphenous veins of sclerosants in microfoam form: long–term outcomes. Phlebology. 2000;15(1):19–23.
74. Roche Rebollo E., Llusá Meléndez Guiu, inventors; Vascular Barcelona Devices, S.L., applicant. Methods, devices, systems and kits for preparing compositions for care and repair of varicose veins. United States patent US 2018/0264417. 2018 Sep 20.
75. Fiorillo AS, Critello CD, Pullano SA, et al. Acoustic cavitation for producing foam in sclerosant drugs. 2015 AEIT International Annual Conference (AEIT); Naples; 2015. p. 1–3. doi:10.1109/AEIT.2015.7415276.
76. Miller DL, Smith NB, Bailey MR, et al. Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med. 2012;31(4):623–634.
77. Fiorillo AS, Grimaldi D, Paolino D, et al. Low–frequency ultrasound in medicine: an in vivo evaluation. IEEE Trans Instrum Meas. 2012;61(6):1658–1663.
78. González I, Rodríguez J, Garmendia I, et al. Application of high intensity air–borne ultrasound for debubbling liquid coating layers. Ultrasonics. 2006;44(suppl (22)):e529–e532.
79. Ross S, McBain JW. Inhibition of foaming in solvents containing known foamers. Ind Eng Chem. 1944;36(6):570–573.
80. Abbas S, Hayat K, Karangwa E, et al. An overview of ultrasound–assisted food–grade nanoemulsions. Food Eng Rev. 2013;5(3):139–157.
81. Leong TS, Wooster TJ, Kentish SE, et al. Minimising oil droplet size using ultrasonic emulsification. Ultrason Sonochem. 2009;16(6):721–727.
82. Saranya N, Devi P, Nithiyanantham S, et al. Cells disruption by ultrasonication. BioNanoScience. 2014;4(4):335–337.
83. Taurozzi JS, Hackley VA, Wiesner MR. Ultrasonic dispersion of nanoparticles for environmental, health and safety assessment–issues and recommendations. Nanotoxicology. 2011;5(4):711–729.
84. Hamel–Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg. 2003;29(12):1170–1175.
85. Ouvry P, Allaert F–A, Desnos P, et al. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2–year follow–up. Eur J Vasc Endovasc Surg. 2008;36(3):366–370.
86. VANISH–1 Investigator Group, JT K, O’Byrne M, Vasquez M, et al. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. Eur J Vasc Endovasc Surg. 2015;50(6):784–793.
87. Gibson K, Kabnick L. A multicenter, randomized, placebo–controlled study to evaluate the efficacy and safety of Varithena (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology. 2017;32(3):185–193.
88. Blaise S, Bosson JL, Diamand JM. Ultrasound–guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double–blind randomised trial with 3–year follow–up. Eur J Vasc Endovasc Surg. 2010;39(6):779–786.
89. Ali H, Elbadawy A, Saleh M, et al. Mid–term results of catheter directed foam sclerotherapy combined with tumescent local anaesthesia for treatment of great saphenous vein incompetence. Eur J Vasc Endovasc Surg. 2017;54(3):363–368.
90. Cavezzi A, Mosti G, Campana F, et al. Catheter foam sclerotherapy of the great saphenous vein, with perisaphenous tumescence infiltration and saphenous irrigation. Eur J Vasc Endovasc Surg. 2017;54(5):629–635.
91. Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg. 2007;94(8):925–936.
92. van Den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta–analysis. J Vasc Surg. 2009;49(1):230–239.
93. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex–guided foam sclerotherapy and duplex–guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg. 2004;30(5):718–722.
94. Gibson K, Gunderson K., Liquid and foam sclerotherapy for spider and varicose veins. Surg Clin North Am. 2018;98(2):415–429.
95. Lawaetz M, Serup J, Lawaetz B, et al. Comparison of endovenous ablation techniques, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Extended 5-year follow-up of a RCT. Int Angiology. 2017;36(3):281–288.
96. Vähäaho S, Halmesmäki K, Albäck A, et al. Five-year follow-up of a randomized clinical trial comparing open surgery, foam sclerotherapy and endovenous laser ablation for great saphenous varicose veins. Br J Surg. 2018;105(6):686–691.
97. Lobascio P, Minafra M, Laforgia R, et al. The use of sclerotherapy with polidocanol foam in the treatment of second–degree haemorrhoidal disease–a video vignette. Colorectal Dis. 2019;21(2):244–245.
98. Barak M, Katz Y. Microbubbles: pathophysiology and clinical implications. Chest. 2005;128(4):2918–2932.
99. Chung EML, Banahan C, Patel N, et al. Size distribution of air bubbles entering the brain during cardiac surgery. PLoS One. 2015;10(4):e0122166.
100. Todd KL, III, Wright DI. The VANISH–2 study: A randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014;29(9):608–618.
101. Star P, Connor DE, Parsi K. Novel developments in foam sclerotherapy: focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins. Phlebology. 2018;33(3):150–162.